From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
CAS Number 173937-91-2
ATC code none
PubChem CID 159594
Chemical data
Formula C29H38N2O6
Molar mass 510.621 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer[1], including non-small cell lung cancer.[2]

It is an endothelin receptor antagonist selective for subtype A (ETA). While other drugs of this type (sitaxentan, ambrisentan) exploit the vasoconstrictive properties of endothelin and are mainly used for the treatment of pulmonary arterial hypertension, atrasentan blocks endothelin induced cell proliferation.


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Atrasentan (entry in the public domain NCI Dictionary of Cancer Terms)
  2. Chiappori, AA; Haura, E; Rodriguez, FA; Boulware, D; Kapoor, R; Neuger, AM; Lush, R; Padilla, B; Burton, M (1 March 2008). "Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer". Clinical Cancer Research. 14 (5): 1464–1469. doi:10.1158/1078-0432.CCR-07-1508. PMID 18316570.